美国联合医疗 UTHR 深 沪
等待开盘 09-03 09:30:00 美东时间
404.81
+100.050
+32.83%
华盛通- 最 高436.95
- 今 开419.63
- 成交量 314.20万股
- 最 低 402.28
- 昨 收 304.76
- 总市值 182.60亿
- 52周最高 436.95
- 市盈率 静 16.43
- 换手率 6.97%
- 52周最低 266.98
- 委 比 83.52%
- 总股本 4510.66万
- 历史最高 436.95
- 量 比 4.23
- 振 幅 11.38%
- 历史最低 36.55
- 每 手 1
- 风险率 51.93%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Why Is United Therapeutics Stock Rallying On Tuesday?
United Therapeutics' Tyvaso showed significant lung function improvement in IPF patients, with plans to seek FDA approval for expanded use.
09-02 22:59
United Therapeutics Stock (UTHR) Rockets 40% on Clinical Trial Results
United Therapeutics stock surged on Tuesday after it reported positive Phase 3 ...
09-02 21:55
MannKind Amends License Agreement with United Therapeutics
MannKind ( ($MNKD) ) just unveiled an announcement. On August 24, 2025, MannKin...
08-27 20:28
United Therapeutics Expands MannKind Deal To Develop Second Inhaled Therapy; MannKind To Receive $5M Upfront, Up To $35M In Milestones, And 10% Royalties
MannKind Corporation (NASDAQ:MNKD) today announced that United Therapeutics Corporation (NASDAQ:UTHR) has exercised its option—granted under the companies' 2018 license and collaboration agreement—to develop a
08-27 20:08
MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy
<p><em>Initial collaboration led to Tyvaso DPI®, the first FDA-approved dry powder inhalation treatment for pulmonary hypertension.</em> MannKind Corporation and United Therapeutics Corporation have expanded their partnership to develop a second dry powder inhalation therapy. Under the agreement, MannKind will formulate a new molecule using its proprietary Technosphere® platform, while United Therapeutics will handle preclinical and clinical deve...
08-27 12:05
UBS Maintains Buy on United Therapeutics, Raises Price Target to $415
UBS analyst Ashwani Verma maintains United Therapeutics (NASDAQ:UTHR) with a Buy and raises the price target from $385 to $415.
08-13 20:16
3D Systems targets $85M in annualized savings by mid-2026 as restructuring accelerates
Earnings Call Insights: 3D Systems Corporation (DDD) Q2 2025 Management View CEO Jeffrey Alan Graves stated that the macro environment for 3D printing OEMs remains challenging, highlighting a year-ove...
08-13 03:31
Liquidia Q2 2025 Earnings Preview
Liquidia (NASDAQ:LQDA) is scheduled to announce Q2 earnings results on Tuesday, August 12th, before market open. The consensus EPS Estimate is -$0.39 (-5.4% Y/Y) and the consensus Revenue Estimate is...
08-11 23:19
United Therapeutics Launches $1 Billion Share Buyback
The latest update is out from United Therapeutics ( ($UTHR) ). On August 1, 202...
08-02 05:49
United Therapeutics enters $1B accelerated share repurchase program
United Therapeutics (NASDAQ:UTHR) has entered into two accelerated share repurchase deal to buy back an aggregate of $1 billion of its common stock. The company will repurchase these shares as part of...
08-01 19:26
